Publications by authors named "Renata de S B Froes"

Article Synopsis
  • The Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) created a national registry to study factors linked to the severity of inflammatory bowel disease (IBD) among Brazilian patients.
  • The study included 1,179 patients, primarily diagnosed with ulcerative colitis (UC) or Crohn's Disease (CD), and found that many had extensive disease, with a significant portion needing biologic treatments.
  • Factors like age, disease extent, and certain complications increased the severity of IBD, particularly for those with extensive colitis or specific disease behaviors.
View Article and Find Full Text PDF

Background: Inflammatory bowel diseases are immune-mediated disorders that include Crohn's disease (CD) and ulcerative colitis (UC). UC is a progressive disease that affects the colorectal mucosa causing debilitating symptoms leading to high morbidity and work disability. As a consequence of chronic colonic inflammation, UC is also associated with an increased risk of colorectal cancer.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD) is an immune-mediated disorder that includes Crohn's disease (CD) and ulcerative colitis. CD is characterized by a transmural intestinal involvement from the mouth to the anus with recurrent and remitting symptoms that can lead to progressive bowel damage and disability over time.

Objective: To guide the safest and effective medical treatments of adults with CD.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD) can lead to social and economic impacts worldwide. In Brazil, where its adult prevalence is increasing, the epidemiology of the pediatric population is not well known, although there is a documented increase in pediatric IBD incidence worldwide. Brazil has continental dimensions, and Espírito Santo is a state of southeastern Brazil, the region with the highest demographic densities and is the economically most important in the country.

View Article and Find Full Text PDF
Article Synopsis
  • Anti-TNF therapy has proven effective in treating ulcerative colitis (UC), but there's limited data on its impact on Brazilian patients; this study compares the efficacy of adalimumab (ADA) and infliximab (IFX) in achieving clinical and endoscopic remission after one year of treatment.
  • Conducted across 24 centers, the study included 393 UC patients and utilized various statistical methods to analyze treatment outcomes, finding that IFX showed better clinical remission rates compared to ADA at 26 and 52 weeks.
  • Results indicated a clinical remission rate of 82.82% at week 52, with IFX patients experiencing fewer instances of loss of response, although endoscopic remission rates did not significantly differ between the
View Article and Find Full Text PDF

Background: Biologics have revolutionized the treatment of inflammatory bowel disease (IBD). However, these drugs had a significant influence on treatment-related costs, which resulted in the development of biosimilars.

Objective: This systematic review and meta-analysis aimed to evaluate the drug discontinuation rate in the IBD population who switched from originator to biosimilars in real-world switching studies and address potential nocebo effects as reasons for drug discontinuation.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the impact of inflammatory bowel disease (IBD) on disability and work absence in Brazil, highlighting a recent increase in prevalence.
  • The analysis reveals that ulcerative colitis (UC) leads to more temporary disabilities, while Crohn's disease (CD) results in longer, more frequent permanent disabilities, particularly affecting younger patients.
  • Findings suggest geographical disparities in disability rates, with higher incidence in the South, particularly for women, and indicate that vocational rehabilitation programs could enhance the quality of life for affected individuals.
View Article and Find Full Text PDF